Myelodysplastic Syndrome Clinical Trial

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Summary

This is a phase 1b/2, open-label, single arm study to evaluate if enasidenib is safe and effective in improving anemia and decreasing transfusion needs in subjects diagnosed with lower risk myelodysplastic syndrome (MDS) or nonproliferative chronic myelomonocytic leukemia (CMML) without a mutation in isocitrate dehydrogenase type 2 (IDH2 wildtype). Other objectives include assessment of improvements in platelet production and characterization of the mechanism of action of enasidenib in enhancing endogenous erythropoiesis.

View Full Description

Full Description

Primary Objective(s)- To determine the efficacy (response rate) of enasidenib in improving anemia and decreasing RBC transfusion dependence.

Secondary Objective(s)- To determine the tolerability, safety and durability of the erythroid response and identify laboratory parameters as clinical markers of response.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Documented diagnosis of 1) MDS according to WHO/FAB classification that meets IRSS-R classification of very low or lower risk disease; and a diagnosed as de novo or secondary MDS (MDS RS eligible if refractory to or declined luspatercept therapy).

OR 2) Dysplastic (nonproliferative) CMML with WBC <13.0/microL)

No disease modifying therapy (HMA, hydrea) within 2 months of starting study
Age ≥ 18 years of age
ECOG ≤ 3
Negative for IDH2 mutation by NGS or multiplex PCR (SNaPshot)

Has symptomatic anemia defined as hemoglobin < 10.0 g/dL with any of the following.

oTachypnea oShortness of breath oFatigue oMalaise oWorsening of cardiovascaular function oAsthenia oDyspnea on exertion oAngina oOther subject symptoms the subject reports as being associated with being anemic.

Stated willingness to comply with all study procedures and availability for the duration of the study
Ability to take oral medication and be willing to adhere to the medication regimen.
Females of reproductive potential need to either commit to true abstinence from heterosexual contact or agree to use, and be able to comply with highly effective contraception without interruption, 28 days prior to starting enasidenib, during the study therapy, and for 30 days after last dose of enasidenib.
For males of reproductive potential: agreement to use of condoms

Adequate organ function defined as:

Hepatic function: total bilirubin <1.5 x ULN (unless attributable to Gilbert's disease), AST or ALT < 3x ULN
Renal function: creatinine clearance >30 mL/minute, calculated by Cockcroft-Gault formula
Ability to understand and the willingness to sign the IRB approved informed consent document.
Women of childbearing potential must have negative urine or serum pregnancy test

Exclusion Criteria:

Use of concurrent other erythropoietic agents (including epoetin, darbepoetin), G-CSF within 30 days of study enrollment
Less than 3 months of life expectancy
Treatment with iron chelation therapy within 56 days of study start
Significant cardiac disease (NYHA Class IV congestive heart failure, or unstable angina or myocardial infarction within the last 6 months
Harbor IDH2 somatic mutations by NGS or PCR
Pregnant or breast feeding
Any uncontrolled bacterial, fungal, viral or other infection.
No known HIV+ or active hepatitis B or C infection, defined as positive viral load for HBV or HCV or a positive surface antigen (HBsAg) test for hepatitis B.
Have other causes of anemia: deficiencies in iron, B12, folate; nutritional deficiencies related to gastric surgery, anorexia nervosa, excessive zinc supplementation; gastrointestinal bleed. If nutritional deficiencies can be corrected, potential participant can be rescreened and enrolled if nutritionally replete and still meets eligibility criteria.
Any other medical history, including laboratory results, deemed by the Principal Investigator likely to interfere with their participation in the study, or to interfere with the interpretation of the results

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 1

Estimated Enrollment:

48

Study ID:

NCT05282459

Recruitment Status:

Recruiting

Sponsor:

Tian Yi Zhang

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Stanford Cancer Institute
Palo Alto California, 94305, United States More Info
Veronica de Santiago
Contact
650-725-4047
[email protected]
Tian Yi Zhang, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Myelodysplastic Syndrome

Phase:

Phase 1

Estimated Enrollment:

48

Study ID:

NCT05282459

Recruitment Status:

Recruiting

Sponsor:


Tian Yi Zhang

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.